Herein we report a novel series of guanidine-modified quinazoline s as NHE-1 inhibitors that also possess anti-inflammatory and antiglycating properties, both of them being important additional mechanisms of action in conditions of systemic inflammation and diabetes mellitus, which are in turn associated with increased cardiovascular risk and retinopathy. The gene discussed is SLC9A1; the disease is retinal disorder.